Metastatic Axillary Lymph Node from Occult Breast Carcinoma: A Case Report
AbstractMetastatic axillary lymph node from occult breast carcinoma poses a difficult and challenging management. It is a rare entity accounting only 0.3-1% cases of all breast cancer. It involves a multidisciplinary discussion and collaboration. Traditionally the treatment consists of mastectomy with axillary lymph node dissection however the practice patterns have steadily changed over the last two to three decades with an emphasized-on breast conservation therapy (BCT). Here we present a 58-year-old lady presented with enlarging right axilla swelling for one month without any breast lump or nipple discharge. Examination revealed 2 mobile right axilla lymph nodes with no palpable breast lump or demonstrable nipple discharge. Routine imaging including mammogram and ultrasound of the breast did not reveal any lesion except suspicious lymph nodes at the right axilla. Cytology of the lymph node showed suspicious of metastatic lesion. Magnetic resonance imaging of the breast also did not reveal any breast lesion. Positron emission tomography and computed tomography (PET CT) was done but did not show uptake to suggest primary lesion except uptake at the right axillary node and right internal mammary node. Excision biopsy of the right axillary node was proven to be metastatic carcinoma in keeping with breast as primary with negative for estrogen and progesterone receptor but c-erB2 positive. Mastectomy with axillary lymph node dissection was done and histopathology report was found to have 2x1 mm, grade 2 tumor in the breast. Patient underwent adjuvant chemotherapy and radiotherapy and currently on trastuzumab and is doing well with no signs of loco regional recurrence or distant metastasis.
Halsted WS. The results of radical operations for the cure of carcinoma of the breast. AnnSurg. 1907; 46: 1-19
Oualla K, Elm’rabey F, Airifi S, Mellas N, Melhouf MA, Bouhafa T et al. Occult primary breast cancer presenting as axillary nodal metastasis: report of 3 cases. Journal of Clinical Gynae and Obsteric. Oct 2012; 1: 85-8
Fayanju OM, Jeffe DB, Margenthaler JA. Journal Surg Res. Dec 2013; 185: 1-8
Zhu YH, Luo MY, Jia Z, Guo JF Diagnoses and therapy of occult breast cancer: A systemic review. Journal of Mol Biomarker and Diagnosis. 2016;2: 1-8
Yadav R, Chauhan P, Sen R, Vashist M. Mammaglobin: As a diagnostic marker for breast cancer. Int journal of recent scientific research. 2015; 6: 7703-7706
Ahmaed I, Dharmarajan K, Tiersten A, Bleiweiss I, Schmidt H, Green S et al. A unique presentation of occult primary breast cancer with review of the literature. Case reports in oncological medicine,2015:1-5
Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M. The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. European Journal of Cancer. 2011;47: 2099-106
Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer, 2010;116: 4000-6
Sohn G, Son BH, Lee SJ, Kang EY, Jung SH, Cho SH et al. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: A nationwide retrospective study. Journal of Surgical Oncology, 2014;110:270-4
Yang H, Li L, Zhang M, Zhang S, Xu S, Ma X. Application of neoadjuvant chemotherapy in occult breast cancer. Medicine, 2017; 96: 40-9
All opinions and reports within the articles that are published in the Gazi Medical Journal are the personal opinions of author(s). Gazi University, Editors and the publisher do not accept any responsibility for these articles. The journal is printed on acid-free paper.